GenVec Issues Patent for Gene Delivery Systems

GenVec, Inc. has issued U.S. Patent 5,846,782, which describes gene delivery systems (vectors) for selectively targeting the transfer of therapeutic genes to specific tissues in the human body. The patent includes a method for altering the surface of a widely used gene therapy vector, the adenovirus, to cause it to bind to receptors found on specific cells within a desired tissue.

"Gene therapy vectors using this patented technology have the potential to be more efficient and selective than currently available vectors," said Paul Fischer, president and CEO of GenVec.

GenVec focuses on the development and commercialization of novel gene therapy products for major disease markets. It is also developing candidates and vector technology in the areas of vascular damage and oncology.